Pepticom is delighted to present our latest publication in the Journal of Immunology

Pepticom is delighted to present our latest article, published in the Journal of Immunology, on the subject of Computationally Designed Bispecific MD2/CD14 Binding Peptides Show TLR4 Agonist Activity. To the best of our knowledge, this is the first example of using Artificial Intelligence for the discovery of novel cyclic peptides; the discovery effort yielded 53 novel bi-specific cyclic ligands for TLR4 co-receptors CD14 and MD2. The 53 discovered peptides are of diverse chemistry and include linear and cyclic peptides with natural and non-natural amino acids (including all D amino acids). The discovered peptides position Pepticom’s platform at the forefront of peptide discovery today. Link to the article: